| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:57 UTC |
|---|
| HMDB ID | HMDB0015363 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Metoclopramide |
|---|
| Description | Metoclopramide is only found in individuals that have used or taken this drug. It is a dopamine D2 antagonist that is used as an antiemetic. [PubChem]Metoclopramide inhibits gastric smooth muscle relaxation produced by dopamine, therefore increasing cholinergic response of the gastrointestinal smooth muscle. It accelerates intestinal transit and gastric emptying by preventing relaxation of gastric body and increasing the phasic activity of antrum. Simultaneously, this action is accompanied by relaxation of the upper small intestine, resulting in an improved coordination between the body and antrum of the stomach and the upper small intestine. Metoclopramide also decreases reflux into the esophagus by increasing the resting pressure of the lower esophageal sphincter and improves acid clearance from the esophagus by increasing amplitude of esophageal peristaltic contractions. Metoclopramide's dopamine antagonist action raises the threshold of activity in the chemoreceptor trigger zone and decreases the input from afferent visceral nerves. Studies have also shown that high doses of metoclopramide can antagonize 5-hydroxytryptamine (5-HT) receptors in the peripheral nervous system in animals. |
|---|
| Structure | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide | ChEBI | | 2-Methoxy-5-chloroprocainamide | ChEBI | | 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide | ChEBI | | 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide | ChEBI | | 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-O-anisamide | ChEBI | | Elieten | ChEBI | | Metoclopramida | ChEBI | | Metoclopramidum | ChEBI | | Reliveran | ChEBI | | Terperan | Kegg | | 4-Amino-5-chloro-2-methoxy-N-(b-diethylaminoethyl)benzamide | Generator | | 4-Amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide | Generator | | Metaclopramide | HMDB | | Metaclopromide | HMDB | | Methochlopramide | HMDB | | Methoclopramide | HMDB | | Metochlopramide | HMDB | | Berk brand OF metoclopramide hydrochloride | HMDB | | Dihydrochloride, metoclopramide | HMDB | | Maxolon | HMDB | | Primperan | HMDB | | Cerucal | HMDB | | Temmler brand OF metoclopramide hydrochloride | HMDB | | Hydrochloride, metoclopramide | HMDB | | Monohydrochloride, metoclopramide | HMDB | | Rimetin | HMDB | | Metoclopramide dihydrochloride | HMDB | | Metoclopramide hydrochloride | HMDB | | Metoclopramide monohydrochloride | HMDB | | Metoclopramide monohydrochloride, monohydrate | HMDB | | Reglan | HMDB |
|
|---|
| Chemical Formula | C14H22ClN3O2 |
|---|
| Average Molecular Weight | 299.796 |
|---|
| Monoisotopic Molecular Weight | 299.14005467 |
|---|
| IUPAC Name | 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide |
|---|
| Traditional Name | metoclopramide |
|---|
| CAS Registry Number | 364-62-5 |
|---|
| SMILES | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC |
|---|
| InChI Identifier | InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19) |
|---|
| InChI Key | TTWJBBZEZQICBI-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Phenol ethers |
|---|
| Sub Class | Aminophenyl ethers |
|---|
| Direct Parent | Aminophenyl ethers |
|---|
| Alternative Parents | |
|---|
| Substituents | - Aminophenyl ether
- Methoxyaniline
- Phenoxy compound
- Anisole
- Methoxybenzene
- Aniline or substituted anilines
- Alkyl aryl ether
- Chlorobenzene
- Halobenzene
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Tertiary aliphatic amine
- Tertiary amine
- Organic 1,3-dipolar compound
- Carboximidic acid
- Carboximidic acid derivative
- Propargyl-type 1,3-dipolar organic compound
- Ether
- Organopnictogen compound
- Organic oxygen compound
- Amine
- Organic nitrogen compound
- Hydrocarbon derivative
- Primary amine
- Organohalogen compound
- Organochloride
- Organonitrogen compound
- Organooxygen compound
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 147.25 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.31 g/L | Not Available | | LogP | 1.8 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 173.2 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.76 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.5118 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.65 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 147.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 556.4 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 208.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 124.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 163.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 56.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 279.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 300.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 580.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 630.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 77.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 661.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 176.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 230.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 502.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 494.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 78.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Metoclopramide,1TMS,isomer #1 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N[Si](C)(C)C)C=C1OC | 2716.6 | Semi standard non polar | 33892256 | | Metoclopramide,1TMS,isomer #1 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N[Si](C)(C)C)C=C1OC | 2546.9 | Standard non polar | 33892256 | | Metoclopramide,1TMS,isomer #1 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N[Si](C)(C)C)C=C1OC | 3148.1 | Standard polar | 33892256 | | Metoclopramide,1TMS,isomer #2 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N)C=C1OC)[Si](C)(C)C | 2453.8 | Semi standard non polar | 33892256 | | Metoclopramide,1TMS,isomer #2 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N)C=C1OC)[Si](C)(C)C | 2448.4 | Standard non polar | 33892256 | | Metoclopramide,1TMS,isomer #2 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N)C=C1OC)[Si](C)(C)C | 3410.4 | Standard polar | 33892256 | | Metoclopramide,2TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N[Si](C)(C)C)C=C1OC)[Si](C)(C)C | 2580.9 | Semi standard non polar | 33892256 | | Metoclopramide,2TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N[Si](C)(C)C)C=C1OC)[Si](C)(C)C | 2495.3 | Standard non polar | 33892256 | | Metoclopramide,2TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N[Si](C)(C)C)C=C1OC)[Si](C)(C)C | 2908.6 | Standard polar | 33892256 | | Metoclopramide,2TMS,isomer #2 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1OC | 2597.0 | Semi standard non polar | 33892256 | | Metoclopramide,2TMS,isomer #2 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1OC | 2570.6 | Standard non polar | 33892256 | | Metoclopramide,2TMS,isomer #2 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1OC | 2931.7 | Standard polar | 33892256 | | Metoclopramide,3TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1OC)[Si](C)(C)C | 2543.5 | Semi standard non polar | 33892256 | | Metoclopramide,3TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1OC)[Si](C)(C)C | 2494.3 | Standard non polar | 33892256 | | Metoclopramide,3TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1OC)[Si](C)(C)C | 2732.7 | Standard polar | 33892256 | | Metoclopramide,1TBDMS,isomer #1 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N[Si](C)(C)C(C)(C)C)C=C1OC | 2920.6 | Semi standard non polar | 33892256 | | Metoclopramide,1TBDMS,isomer #1 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N[Si](C)(C)C(C)(C)C)C=C1OC | 2774.2 | Standard non polar | 33892256 | | Metoclopramide,1TBDMS,isomer #1 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N[Si](C)(C)C(C)(C)C)C=C1OC | 3196.8 | Standard polar | 33892256 | | Metoclopramide,1TBDMS,isomer #2 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N)C=C1OC)[Si](C)(C)C(C)(C)C | 2712.6 | Semi standard non polar | 33892256 | | Metoclopramide,1TBDMS,isomer #2 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N)C=C1OC)[Si](C)(C)C(C)(C)C | 2642.4 | Standard non polar | 33892256 | | Metoclopramide,1TBDMS,isomer #2 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N)C=C1OC)[Si](C)(C)C(C)(C)C | 3414.0 | Standard polar | 33892256 | | Metoclopramide,2TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N[Si](C)(C)C(C)(C)C)C=C1OC)[Si](C)(C)C(C)(C)C | 2983.0 | Semi standard non polar | 33892256 | | Metoclopramide,2TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N[Si](C)(C)C(C)(C)C)C=C1OC)[Si](C)(C)C(C)(C)C | 2871.9 | Standard non polar | 33892256 | | Metoclopramide,2TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N[Si](C)(C)C(C)(C)C)C=C1OC)[Si](C)(C)C(C)(C)C | 3088.1 | Standard polar | 33892256 | | Metoclopramide,2TBDMS,isomer #2 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1OC | 3045.5 | Semi standard non polar | 33892256 | | Metoclopramide,2TBDMS,isomer #2 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1OC | 2957.6 | Standard non polar | 33892256 | | Metoclopramide,2TBDMS,isomer #2 | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1OC | 3058.7 | Standard polar | 33892256 | | Metoclopramide,3TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1OC)[Si](C)(C)C(C)(C)C | 3131.9 | Semi standard non polar | 33892256 | | Metoclopramide,3TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1OC)[Si](C)(C)C(C)(C)C | 3069.7 | Standard non polar | 33892256 | | Metoclopramide,3TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=CC(Cl)=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1OC)[Si](C)(C)C(C)(C)C | 3013.3 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Metoclopramide GC-MS (Non-derivatized) - 70eV, Positive | splash10-001r-9610000000-b6fe5f492b0d4ca6c150 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Metoclopramide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-004i-0090000000-10fdf9db1550886fc034 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-0udi-0009000000-fcc278321866ecdee26f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-004i-0193000000-c044c04d9d51d66ba5a9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-004i-0290000000-45d3c52d766c4cd8ae93 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-003r-0970000000-2f2d709cad2c27f798e5 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-001i-0920000000-ccce0f42f04edf0ecfb3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-00lr-0900000000-93aec7dddb8a098f7483 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-0udi-0009000000-e7b25ddf867c24be5347 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-004i-0093000000-dc0ce524de60c6a189a7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-004i-0290000000-2bca02d9f4cee5acca4e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-003r-0970000000-50fe530dffb9aa59d433 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-001i-0920000000-0bb9973fdbe0820dc3d1 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-00lr-0900000000-4cc6fae9bec9d4c40dbb | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide LC-ESI-ITFT , positive-QTOF | splash10-004i-0090000000-1c4a27b221c7a053d2c3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide , positive-QTOF | splash10-0fb9-0595000000-db3b50f051cfcc835a69 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide 15V, Positive-QTOF | splash10-0ufr-0069000000-93c3839d751c69450f14 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide 10V, Positive-QTOF | splash10-0ufr-0069000000-81fd95d3b4b8a739b1b5 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide 35V, Positive-QTOF | splash10-004i-0290000000-6741a21b4bd686e97955 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Metoclopramide 75V, Positive-QTOF | splash10-004l-9400000000-e6a69fee2535079fef49 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Metoclopramide 10V, Positive-QTOF | splash10-0udi-1759000000-14b767e1985b55c13727 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Metoclopramide 20V, Positive-QTOF | splash10-0ugr-4940000000-2016fe8b0b0d4e5aa870 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Metoclopramide 40V, Positive-QTOF | splash10-0fk9-9500000000-94bfb5af9b1e4e11a705 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Metoclopramide 10V, Negative-QTOF | splash10-0002-0190000000-6b24c4fdc3e3fbf344c7 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Metoclopramide 20V, Negative-QTOF | splash10-0002-2590000000-1429e8508288721a0e7a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Metoclopramide 40V, Negative-QTOF | splash10-0596-9810000000-f5f978ef1ee636729e5f | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|